MedDataX Logo

GLP-1's Effect on Cardiac Parameters and Mesenteric Blood Flow

NCT ID: NCT01988545

Last Updated: 2013-11-20

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

8 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-11-30

Study Completion Date

2014-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

to investigate the effect of the human incretin hormone GLP-1 on mesenteric blood flow and cardiac parameters

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

to investigate the effect of the human incretin hormone GLP-1 on mesenteric blood flow and cardiac parameters, in healthy subjects, 4 arms, task force monitor

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

GLP-1 blood flow cardiac out put stroke volume beat to beat effect of GLP-1 on cardiac parameters and blood flow

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

DOUBLE

Participants Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

GLP-1

1,5 nmol/kg,GLP-1 sc injection

Group Type ACTIVE_COMPARATOR

1,5 nmol/kg GLP-1 9-36amide, sc injection

Intervention Type OTHER

Exendin-4 ;10 ug,sc injection

Intervention Type OTHER

GLP-1 9-36amide

1,5 nmol/kg GLP-1 9-36amide, sc injection

Group Type ACTIVE_COMPARATOR

1,5 nmol/kg,GLP-1 sc injection

Intervention Type OTHER

Exendin-4 ;10 ug,sc injection

Intervention Type OTHER

Exendin-4

Exendin-4 ;10 ug,sc injection

Group Type ACTIVE_COMPARATOR

1,5 nmol/kg,GLP-1 sc injection

Intervention Type OTHER

1,5 nmol/kg GLP-1 9-36amide, sc injection

Intervention Type OTHER

isotonic saline

2 ml of isotonic saline, sc injection

Group Type PLACEBO_COMPARATOR

1,5 nmol/kg,GLP-1 sc injection

Intervention Type OTHER

1,5 nmol/kg GLP-1 9-36amide, sc injection

Intervention Type OTHER

saline

Intervention Type OTHER

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

1,5 nmol/kg,GLP-1 sc injection

Intervention Type OTHER

1,5 nmol/kg GLP-1 9-36amide, sc injection

Intervention Type OTHER

Exendin-4 ;10 ug,sc injection

Intervention Type OTHER

saline

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

native GLP-1

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* healthy subjects

Exclusion Criteria

* medical conditions
Minimum Eligible Age

20 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Copenhagen

OTHER

Sponsor Role collaborator

Glostrup University Hospital, Copenhagen

OTHER

Sponsor Role collaborator

Zealand University Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

MD ph.d. Lasse Bremholm

MD, ass. professor, ph.d

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Lasse Bremholm, MD, ph.d.

Role: PRINCIPAL_INVESTIGATOR

Køge Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Køge Hospital

Køge, State..., Denmark

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Denmark

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Lasse Bremholm, MD, ph.d.

Role: CONTACT

Phone: 0004560927874

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

lasse bremholm, MD, ph.d.

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2013.GLP-1

Identifier Type: -

Identifier Source: org_study_id